Sound Pharma Announces Positive Phase 3 Results for the Treatment of Meniere’s Disease with SPI-1005

Sound Pharmaceuticals announced that its Phase 3 trial of SPI-1005 (ebselen) for Meniere’s Disease met co-primary efficacy endpoints, improving hearing loss and speech discrimination. Meniere’s Disease, a disorder causing hearing loss, tinnitus, and vertigo, currently has no FDA-approved treatments.